This is an actively managed healthcare exchange-traded fund run by iShares, using a strategy that seeks opportunities in innovative and emerging medical companies. Rather than replicating a specific index, it relies on management judgment about the underlying companies' business environments and research results, and that judgment shapes the portfolio.

It concentrates on the growth potential of innovative medical companies rather than healthcare as a whole, making it suitable for investors who can tolerate short-term performance swings and thematic concentration risk.

It is an ETF managed by iShares using an active management approach.

Rather than following a specific index, BMED ETF selects healthcare innovation areas based on the underlying companies' technological competitiveness, clinical development stages, regulatory environment, and monetization potential. Because it is actively managed, its holdings and sector weights may change depending on management judgment, and its results may differ from those of conventional index-based products.

• Active management that emphasizes company selection over replicating a specific index
• Thematic exposure focused on innovative medicine and emerging healthcare companies

Assets under management (AUM) stand at $14.8M, and the total expense ratio (Expense Ratio) is 0.55% per year.

Unlike index-tracking products, active strategies are heavily influenced by management judgment. Beyond the fee burden and trading conditions, it is therefore important to check the criteria used to select investments and the potential for portfolio changes.

The healthcare innovation theme can react sharply to individual events such as clinical results, regulatory decisions, research and development progress, and merger and acquisition expectations. Because BMED ETF holds companies exposed to these factors, its returns may move in a different direction from the broader market.

Fund flows into thematic healthcare products can be affected by the interest rate environment, risk appetite, drug development news, and the sector outlook. Even when investment demand is rising, performance gaps between individual companies within the theme are large, so investors should examine inclusion criteria and volatility rather than judging the strategy's quality by inflows alone.

Active company selection and healthcare innovation exposure are its strengths, while thematic concentration and portfolio changes driven by management judgment are risks worth noting.

Among the ETFs in the table, DRAM ETF focuses on memory companies, SECT ETF on sector rotation, AVRE ETF on real estate, VOLT ETF on electrification, and CANC ETF on the oncology theme. Their underlying exposures and management objectives differ from those of BMED ETF, so they are better viewed not as direct substitutes but as comparison references for each theme's concentration, fee burden, and asset size. Because listing information on comparable healthcare innovation products is limited, investors should first compare the general industry and risk structure.

Before investing, check the selection criteria of the active management, the concentration of the healthcare innovation theme, the distribution history, and the impact of exchange rates. Because BMED ETF is structured differently from index-replicating products, it is advisable to first decide your holding purpose and the range of volatility you can tolerate.

News on clinical trials and regulation, differences in research and development results, and shifts in market risk appetite can amplify the volatility of holdings. Given the nature of overseas stocks and thematic products, exchange rate and liquidity conditions can also affect perceived returns in Korean won terms, so investors should consider diversification as well.

BMED ETF has a structure suited to investors who want active exposure to the healthcare innovation area, but the lack of distribution history and thematic concentration risk must be taken into account. It is advisable to approach it only after confirming that the differences from index-based healthcare products, the cost burden, and the influence of management judgment fit your investment horizon and goals.